Analyst: Novo’s heavy artillery
The European approval of Novo Nordisk’s long-acting insulin Tresiba is not a great surprise to analyst Søren Løntoft Hansen. He highlights one aspect of the approval, which will help the Danes in the battle with rival Sanofi.
by Stefan Singh Kailay
The news about the EU commission’s approval of Tresiba was not a huge surprise, as the drug had already been recommended by the medicines committee CHMP under the EMA.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Tresiba finally gains EU-approval
For abonnenter
